Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review

por Chen, Monica F., Chaft, Jamie E.
Publicado 2023

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report

por Thummalapalli, Rohit, Choudhury, Noura J., Ehrich, Fiona, Beardslee, Tyler, Brazel, Danielle, Zhang, Shannon S., Merchant, Shelby, Chen, Monica F., Heller, Glenn, Ramalingam, Suresh S., Ou, Sai-Hong Ignatius, Mileham, Kathryn F., Riely, Gregory J.
Publicado 2023